VIR - Vir Biotechnology, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
VIR price evolution
VIR
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $310.81 | $174.05 | $254.84 | |
| Short term investments | $854.2 | $989.05 | $1280.83 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1047.16 | $1205.74 | $1213.1 | $1588.23 |
| Long term investments | $286.36 | $366.15 | $111.72 | |
| Property, plant & equipment | $125.57 | $128.33 | $162.82 | $167.2 |
| Goodwill & intangible assets | $35.84 | $39.4 | $39.5 | |
| Total noncurrent assets | $463.81 | $580.87 | $330.83 | |
| Total investments | $1140.56 | $1355.2 | $1392.56 | |
| Total assets | $1498.36 | $1669.56 | $1793.97 | $1919.06 |
| Current liabilities | ||||
| Accounts payable | $7.3 | $4.39 | $7.11 | $6.33 |
| Deferred revenue | $16.7 | $16.22 | $66.38 | |
| Short long term debt | ||||
| Total current liabilities | $117.16 | $96.41 | $94.07 | $175.41 |
| Long term debt | $95.02 | $109.17 | $111.67 | |
| Total noncurrent liabilities | $139.47 | $152.54 | $153.42 | |
| Total debt | $95.02 | $109.17 | $111.67 | |
| Total liabilities | $257.63 | $235.88 | $246.61 | $328.82 |
| Shareholders' equity | ||||
| Retained earnings | -$655.2 | -$441.48 | -$303.1 | -$237.82 |
| Other shareholder equity | -$2.88 | -$2.4 | -$0.81 | |
| Total shareholder equity | $1433.67 | $1547.36 | $1590.24 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $254.84 | $861.31 | $356.41 | $444.57 |
| Short term investments | $1280.83 | $1553.41 | $360.33 | $300.29 |
| Net receivables | $773.08 | |||
| Inventory | ||||
| Total current assets | $1588.23 | $2519.08 | $1562.82 | $772.37 |
| Long term investments | $111.72 | $30.58 | $208.39 | $6.92 |
| Property, plant & equipment | $167.2 | $188.17 | $130.05 | $79.89 |
| Goodwill & intangible assets | $39.5 | $49.69 | $50.22 | $50.76 |
| Total noncurrent assets | $330.83 | $283.01 | $391.45 | $146.4 |
| Total investments | $1392.56 | $1583.99 | $568.72 | $307.2 |
| Total assets | $1919.06 | $2802.09 | $1954.27 | $918.76 |
| Current liabilities | ||||
| Accounts payable | $6.33 | $6.42 | $6.52 | $5.08 |
| Deferred revenue | $66.38 | $68.72 | $102.02 | $10.27 |
| Short long term debt | ||||
| Total current liabilities | $175.41 | $511.03 | $341.24 | $99.06 |
| Long term debt | $111.67 | $123.84 | $133.56 | $66.56 |
| Total noncurrent liabilities | $153.42 | $213.1 | $181.18 | $102.84 |
| Total debt | $111.67 | $123.84 | $133.56 | $66.56 |
| Total liabilities | $328.82 | $724.13 | $522.42 | $201.91 |
| Shareholders' equity | ||||
| Retained earnings | -$237.82 | $377.24 | -$138.6 | -$667.18 |
| Other shareholder equity | -$0.81 | -$9.12 | -$1.1 | -$1.28 |
| Total shareholder equity | $1590.24 | $2077.96 | $1431.85 | $716.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.38 | $3.08 | $56.38 | $16.79 |
| Cost of revenue | $0.05 | $0.06 | $0.8 | |
| Gross Profit | $2.33 | $3.02 | $56.32 | $15.99 |
| Operating activities | ||||
| Research & development | $105.11 | $100.13 | $111.92 | |
| Selling, general & administrative | $30.27 | $36.27 | $43.09 | |
| Total operating expenses | $220.92 | $161.65 | $136.4 | $155 |
| Operating income | -$158.63 | -$80.08 | -$139.02 | |
| Income from continuing operations | ||||
| EBIT | -$139.89 | -$65 | -$120.76 | |
| Income tax expense | $0.18 | -$1.51 | $0.28 | -$4.78 |
| Interest expense | $18.66 | |||
| Net income | ||||
| Net income | -$213.72 | -$138.38 | -$65.28 | -$115.97 |
| Income (for common shares) | -$138.38 | -$65.28 | -$115.97 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $86.18 | $1615.8 | $1095.41 | $76.37 |
| Cost of revenue | $2.77 | $146.32 | $65.86 | |
| Gross Profit | $83.42 | $1469.48 | $1029.55 | $76.37 |
| Operating activities | ||||
| Research & development | $589.67 | $474.65 | $448.01 | $302.41 |
| Selling, general & administrative | $178.05 | $161.76 | $160.79 | $70.94 |
| Total operating expenses | $767.72 | $636.41 | $608.8 | $373.35 |
| Operating income | -$684.3 | $833.07 | $420.75 | -$296.98 |
| Income from continuing operations | ||||
| EBIT | -$628.14 | $754.28 | $549.8 | -$298.61 |
| Income tax expense | -$13.08 | $238.44 | $21.22 | $0.05 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$615.06 | $515.84 | $528.58 | -$298.67 |
| Income (for common shares) | -$615.06 | $515.84 | $528.58 | -$298.67 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$138.38 | -$65.28 | -$115.97 | |
| Operating activities | ||||
| Depreciation | $5.73 | $5.96 | $5.92 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $22.16 | $23.76 | $28.27 | |
| Total cash flows from operations | -$77.85 | -$109.39 | -$107.93 | |
| Investing activities | ||||
| Capital expenditures | -$0.29 | -$1.34 | -$1.53 | |
| Investments | $211.89 | $29.76 | -$103.28 | |
| Total cash flows from investing | $358.63 | $211.61 | $28.42 | -$104.81 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.01 | $0.22 | $1.77 | |
| Net borrowings | -$0.07 | -$0.07 | -$0.09 | |
| Total cash flows from financing | $3.13 | $2.94 | $0.15 | $1.68 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.04 | $136.7 | -$80.82 | -$211.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$615.06 | $515.84 | $528.58 | -$298.67 |
| Operating activities | ||||
| Depreciation | $27.11 | $15.49 | $11.98 | $8.81 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $111.32 | $102.08 | $83.78 | $27.6 |
| Total cash flows from operations | -$778.78 | $1663.25 | -$47.59 | -$190.94 |
| Investing activities | ||||
| Capital expenditures | -$21.57 | -$68.01 | -$21.82 | -$6.55 |
| Investments | $186.2 | -$1125.45 | -$119 | -$3.49 |
| Total cash flows from investing | $164.63 | -$1193.46 | -$140.81 | -$9.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.77 | $36.22 | $100.59 | $533.97 |
| Net borrowings | -$0.29 | -$0.26 | -$0.26 | -$0.25 |
| Total cash flows from financing | $7.48 | $34.76 | $100.33 | $529.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$606.68 | $504.55 | -$88.07 | $328.67 |
News
Fundamentals
| Market cap | $1.00B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 136.71M |
| Revenue | $78.62M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$533.34M |
| Revenue Q/Q | -9.81% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.88 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 12.76 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.90 |
|---|---|
| ROA | -31.00% |
| ROE | N/A |
| Debt/Equity | 0.21 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.94 |
| Quick ratio | N/A |